Literature DB >> 35110334

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.

Peter C Grayson1, Cristina Ponte2,3, Ravi Suppiah4, Joanna C Robson5, Anthea Craven6, Andrew Judge6,7, Sara Khalid6, Andrew Hutchings8, Raashid A Luqmani6, Richard A Watts6,9, Peter A Merkel10.   

Abstract

OBJECTIVE: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA).
METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate criteria items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators.
RESULTS: The development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1×109/L (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti-proteinase 3-ANCA positivity (-3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1) and haematuria (-1). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% CI 77% to 91%) and the specificity was 99% (95% CI 98% to 100%).
CONCLUSION: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis demonstrate strong performance characteristics and are validated for use in research. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arthritis; autoimmune diseases; rehabilitation

Mesh:

Substances:

Year:  2022        PMID: 35110334     DOI: 10.1136/annrheumdis-2021-221794

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   27.973


  13 in total

1.  Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy.

Authors:  Yong Zhong; Xiangcheng Xiao; Qi Xiong; Wei Lin; Chanjuan Shen; Ting Meng; Rong Tang; Joshua D Ooi; Peter J Eggenhuizen; Jinbiao Chen; Wannian Nie; Xia Li; Qiaoling Zhou; Ping Xiao
Journal:  Immunol Res       Date:  2022-10-13       Impact factor: 4.505

2.  New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors.

Authors:  Jan Holubar; Erik Arnaud; Jonathan Broner; Yves-Marie Pers; Alain Proust; Radjiv Goulabchand
Journal:  Immunol Res       Date:  2022-09-20       Impact factor: 4.505

3.  A Surgical Presentation of Churg-Strauss Syndrome.

Authors:  Nikhil Vasandani; Martha Isaac; Amrit Bajwa; Margaret Sheehan; Emmeline Nugent
Journal:  Cureus       Date:  2022-04-21

Review 4.  Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.

Authors:  Adél Molnár; Péter Studinger; Nóra Ledó
Journal:  Front Med (Lausanne)       Date:  2022-06-03

5.  ANCA-Negative Vasculitis in Eosinophilic Granulomatosis with Polyangiitis Complicated with Membranous Nephropathy: A Case Report and Brief Literature Review.

Authors:  Eri Kasama; Jun Ino; Fumika Iemura; Saeko Kumon; Mio Kodama; Keitaro Sato; Hitoshi Eizumi; Kosaku Nitta; Junichi Hoshino
Journal:  Case Rep Nephrol       Date:  2022-05-06

Review 6.  Global epidemiology of vasculitis.

Authors:  Richard A Watts; Gulen Hatemi; Jane C Burns; Aladdin J Mohammad
Journal:  Nat Rev Rheumatol       Date:  2021-12-01       Impact factor: 20.543

7.  Clinical Significance of Antineutrophil Cytoplasmic Antibody Positivity in Patients Infected with SARS-CoV-2.

Authors:  Lucy Eunju Lee; Wooyong Jeong; Yong-Beom Park; Su Jin Jeong; Sang-Won Lee
Journal:  J Clin Med       Date:  2022-07-17       Impact factor: 4.964

Review 8.  The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs.

Authors:  Yasutaka Kimoto; Takahiko Horiuchi
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

9.  The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.

Authors:  Allyson C Egan; Andreas Kronbichler; Irmgard Neumann; Alessandra Bettiol; Nicholas Carlson; Maria C Cid; Giacomo Emmi; Seerapani Gopaluni; Lorraine Harper; Thomas Hauser; Mark A Little; Raashid A Luqmani; Alfred Mahr; Mark McClure; Aladdin J Mohammad; Karl Emil Nelveg-Kristensen; Sophie Ohlsson; Chen Au Peh; Matthew Rutherford; Beatriz Sanchez Alamo; Jennifer Scott; Mårten Segelmark; Rona M Smith; Wladimir M Szpirt; Gunnar Tomasson; Giorgio Trivioli; Augusto Vaglio; Michael Walsh; Maria Wester Trejo; Kerstin Westman; Ingeborg M Bajema; David R W Jayne
Journal:  Kidney Int Rep       Date:  2022-05-25

10.  A case report of myocarditis secondary to eosinophilic granulomatosis with polyangiitis.

Authors:  Dorina-Gabriela Condurache; Zahra Raisi-Estabragh; Rohit Baslas; Shahir Hamdulay
Journal:  Eur Heart J Case Rep       Date:  2022-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.